Seattle-based VisionGate is moving its 21 employees to the Phoenix Biomedical Campus, becoming the first for-profit developer to take up residence in the development. It will share a building with Translational Genomics Research Institute and the International Genomics Consortium.
VisionGate's Cell-CT platform produces high resolution 3D images that allow researchers to see cells turning cancerous. The city of Pheonix is purchasing two of the devices for $1.2 million so that other researchers in the area will be able to take advantage of the imaging techology.
The company is looking to expand and expects to more than double its headcount in the next 18 months, according to company CEO Alan Nelson.
- here's the story on VisionGate